More real medical news…
From the press release:
IGI, INC. announced that it has received, a Small Business Technology Transfer (STTR) grant from the National Cancer Institute to evaluate the safety and therapeutic potential of parathyroid hormone PTH (7-34) analog to treat alopecia induced by chemotherapy in breast cancer patients.
In previous animal testing, IGI “successfully formulated PTH 7-34 into its proprietary Novasome encapsulation technology, and the treatment both stimulated and maintained hair growth in mice. This next round of testing will be performed on human subjects under the oversight of Dr. Michael Holick at Boston University.

I came across this press release for IGI, Inc., a New Jersey based company that is “committed to growth by applying proprietary technologies to achieve cost-effective solutions for varied customer needs.” (Is that management double-speak or what?) Their technologies focus on methods of delivering skin care products, and their customer list includes big names such as Johnson & Johnson and Estee Lauder.
Here’s the point of relevence, from the press release:
IGI is also exploring the licensing of the topical PTH (7-34) compound for the prevention/treatment of chemotherapy induced-alopecia in patients undergoing chemotherapy.
PTH, that is parathyroid hormone, therapies may have the ability …read more